BioSpace News Archive

Yumanity Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced it has entered into definitive agreements for two strategic transactions.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral liver diseases, announced an update on the timing of its pre-submission meeting with the U.S. Food and Drug Administration regarding the potential resubmission of its nonalcoholic steatohepatitis New Drug Application based on an interim analysis of the REGENERATE trial in patients with fibrosis due to NASH.

Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), presented updated clinical data from its clinical trials of KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous melanoma (mCM) and metastatic uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the 2022 BIO International Convention being held June 13-16, 2022 in San Diego, CA.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that a poster detailing the benefits of the Company’s Portable Neuromodulation Stimulator (“PoNS”) Therapy combined with a therapeutic exercise program was presented at the 2022 Consortium of Multiple Sclerosis Centers (“CMSC”) Annual Meeting.

XORTX Therapeutics Inc. is pleased to welcome and appoint Mr. Anthony Giovinazzo to the Board of Directors and as Chair of the Board.

Tiziana Life Sciences Ltd (NASDAQ: TLSA) (" Tiziana " or the " Company "), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies via novel routes of administration today announced that its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will present at the Biotechnology Innovation Organization (BIO) Annual Convention taking place at the San Diego Convention Center, Monday June 13 - Thursday, June 16, 2022.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its presence at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting to be held in Vancouver from June 11-14.

NT-I7 plus pembrolizumab showed anti-tumor activity in heavily pretreated patients for whom checkpoint inhibitors are usually ineffective.

Seven Presentations Will Include Unique Research on the New Biotrue ® Hydration Plus Multi-Purpose Solution and Biotrue ® Hydration Boost Lubricant Eye Drops.